Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus|xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’ CAP/CLIA laboratory located in Research Triangle Park in North Carolina.

xT is now covered for Medicare patients under the MolDx program for tumor-only as well as normal match sequencing in all solid tumors, and tumor sequencing for patients with myeloid and suspected myeloid malignancies. xT is covered for Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing (NGS) of tumor tissue to optimize treatment selection decisions.

“We’re pleased that Medicare is advancing coverage for biomarker testing for patients with both solid tumor and hematologic cancers,” said Eric Lefkofsky, Founder and CEO of Tempus. “This step provides wider access to the tools physicians need to optimize treatment decisions for their patients.”

xT is a DNA sequencing panel that provides a comprehensive view of patients’ genomic profiles, equipping physicians to make informed treatment decisions. The assay identifies clinically relevant alterations, immunotherapy biomarkers such as MSI and TMB, as well as incidental germline findings.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231115761937/en/